AM-926

AM-926 is a drug that acts as a potent and selective agonist for the cannabinoid receptor CB1. It has been used in its 11C radiolabelled form to map the distribution of CB1 receptors in the brain, using positron emission tomography (PET).

Chemistry

AM-926 is a derivative of the classical cannabinoid ligand HU-210, which is itself a derivative of Δ9-THC, the main active component of cannabis. The structure of AM-926 includes a quinoline ring, which is not present in most other cannabinoid ligands.

Pharmacology

AM-926 acts as a full agonist at the CB1 receptor, with a binding affinity (Ki) of 0.8 nM, making it around 25 times more potent than Δ9-THC. It has been used in its 11C radiolabelled form to map the distribution of CB1 receptors in the brain, using positron emission tomography (PET).

Research

Research on AM-926 and similar drugs is focused on their potential use in the treatment of various medical conditions, including pain, obesity, neurodegenerative diseases, and mental disorders such as schizophrenia and depression.

See also

• Cannabinoid receptor
• Cannabinoid
• HU-210
• Δ9-THC
• Positron emission tomography

AM-926 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia